Enduring Material

- https://www.cms.org

• The State of Colorado Department of Regulatory Agencies has determined that there is a knowledge gap around addiction treatment, and have therefore made it a requirement for prescribers to have additional hours of education on this topic in order to be eligible for re-licensure.

• At the end of this activity, the learner will be able to articulate what the Contingency Management model for treating stimulant and other substance use disorders is, as well as be able to summarize the effectiveness of treatment, incentive options, outcomes for diverse populations, and the cost-benefit analysis of the model.
• Analyze barriers to implementing Contingency Management; including restrictions on the use of federal funds, logistics, inducement, and stigma.
• Compare and contrast findings from interviews with Colorado behavioral health providers and other stakeholders on the gaps and needs which should be addressed to implement contingency management across Colorado, along with a summary of potential funding sources to enable the creation of more programs.

• The Colorado Medical Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

The State of Colorado Department of Regulatory Agencies has determined that there is a knowledge gap around addiction treatment, and has therefore made it a requirement for prescribers to have additional hours of education on this topic in order to be eligible for re-licensure.

At the end of this activity, the learner will be able to articulate what the Contingency Management model for treating stimulant and other substance use disorders is, as well as be able to summarize the effectiveness of treatment, incentive options, outcomes for diverse populations, and the cost-benefit analysis of the model.

CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Joshua Blum, MD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

This activity does not have commercial support from any ACCME defined ineligible company. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

70 %

100 %

6/25/2024